Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
February 27, 2006
- AstraZeneca Starts IPAS Study on Iressa to Verify Efficacy in Orientals
February 27, 2006
- Toho to Focus on Quality of Services, Not Share: President Hamada
February 27, 2006
- Takeda Licenses Hematide from Affymax
February 27, 2006
- Replidyne, Forest to Comarket Faropenem Medoximil: Daiichi Asubio
February 27, 2006
- Kyorin Licenses KRP-203 to Novartis
February 27, 2006
- SURVEY 4 articles
February 27, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 27, 2006
- Roche Diagnostics Launches JMCoE Program Aiming at Personalized Medicine
February 27, 2006
- Drugs' Contribution to Medical Expenditure Optimization Is 0.7%: Mr Futagawa
February 27, 2006
- New Products to Offset Impact of NHI Price Cut: DSP
February 27, 2006
- New Prescription Form, Dispensing Fees Approved
February 27, 2006
- Initial Consultation Fee to Be Unified for Hospitals and Clinics
February 27, 2006
- REGULATORY NEWS IN BRIEF
February 27, 2006
- Olympus: Medical, Life Science Businesses Show Growth in 1st 3 Qtrs
February 27, 2006
- US FDA Accepts NDA for Garenoxacin: Toyama Chemical
February 27, 2006
- NEW PRODUCTS
February 27, 2006
- Continuing Reform Essential to Stabilize Social Security Systems: Health Minister Kawasaki
February 27, 2006
- SELF-MEDICATION NEWS IN BRIEF
February 27, 2006
- Varied Reactions Shown to New Medical Fees
February 27, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…